Navigation Links
Genetic variants predict recurrence of bladder cancer, patient survival
Date:4/20/2009

DENVER - Scientists at The University of Texas M. D. Anderson Cancer Center have discovered genetic variations in the inflammation pathway that reduce the likelihood of recurrence and increase survival of patients with non-muscle invasive bladder cancer (NMIBC) who are treated with mainstream therapy.

Patients with risk-reducing genotypes were 84 percent less likely to have their disease recur after treatment with Bacillus Calmette-Guerin (BCG), the prevailing immunotherapy to prevent high-risk NMIBC patients from developing recurrence. The recurrence-free median survival time among these patients was 96.7 months compared with 47 months among those with the more typical genotype, the team reported at the 100th Annual Meeting of the American Association for Cancer Research.

"The future purpose of this kind of study is personalized cancer therapy," said senior author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology at M. D. Anderson. "This genetic information is an essential step toward constructing a blueprint that will determine treatment response and follow-up strategy."

Currently, the primary treatment for NMIBC is transurethral resection - surgical removal of the tumor tissues from bladder - combined with chemotherapy or immunotherapy such as BCG injection. Overall, the recurrence rate is around 50 percent over four years.

In this study of 596 patients at M. D. Anderson, 46 percent of those who had a common genotype of the inducible nitric oxide synthase (iNOS) gene experienced a recurrence after receiving maintenance BCG therapy. Only 22 percent of patients with the variant-containing genotypes had a recurrence with the same treatment. The results suggest that BCG may be more effective when administered to individuals with genotypes containing the variant allele of the iNOS gene.

"We aimed to determine why some patients respond to BCG and others don't," said lead author Hushan Yang, Ph.D., a postdoctoral fellow in the Department of Epidemiology at M. D. Anderson.

Yang and his colleagues evaluated 59 single nucleotide polymorphisms (SNPs) in 35 major inflammation genes. Using a combined analysis, they stratified patients into multiple risk groups. Those patients in the high-risk group were found to have a median survival time of only 13.5 months, while those in the low-risk group were recurrence free for more than 96.7 months.

"Once validated, the next step will be to create a risk prediction model," said Wu. "Combining the information we have with other aspects such as clinical, epidemiological and behavioral variables, as well as tumor characteristics, patient characteristics and other genetic information will allow treating physicians to know whether their patient is likely to respond to therapy or experience a recurrence."


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Genetic source of rare childhood cancer found; gene is implicated in other cancers
2. Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics
3. Genetic risk factors play role in autoantibody-negative rheumatoid arthritis
4. Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board
5. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
6. Genetic Finding May Lead to Male Contraceptive
7. Genetic link uncovered in disparate colon cancer death
8. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
9. Roberta A. Pagon Receives Lifetime Award in Genetics from March of Dimes
10. Genetic changes outside nuclear DNA suspected to trigger more than half of all cancers
11. Researchers Suspect Genetic Link to COPD
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetic variants predict recurrence of bladder cancer, patient survival
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
Breaking Medicine Technology: